Predicting immune-related side effects in cancer treatment
Official title: Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events
Funded at University of Tx Md Anderson Can Ctr · NIH-11013436 · Data updated 2026-11-12
This study is looking to help cancer patients who are getting immune treatments by figuring out who might be more likely to have side effects related to their immune system, so doctors can catch and manage these issues early on to improve their overall treatment experience.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 19, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $591,407 |
| NIH project number | 5R01CA279749-02 |
| Project ID | NIH-11013436 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who are being treated with immune checkpoint inhibitors and are at risk for experiencing severe immune-related adverse events.
✕Less likely to help
Patients who are not receiving immune checkpoint inhibitors or those with conditions unrelated to cancer treatment may not benefit from this research.
What this research studies
This research focuses on understanding and predicting the immune-related adverse events (irAEs) that can occur in patients receiving immune checkpoint inhibitors (ICPis) for cancer treatment. By integrating patient-reported outcomes with T-cell receptor sequencing, the study aims to develop a risk-prediction model that identifies patients at higher risk for severe irAEs. This approach will help in early detection and management of these side effects, potentially improving treatment outcomes and quality of life for patients. The research is centered on patient experiences and aims to create a clinical tool that can be used in practice.
Why it matters
Potential benefit: If successful, this research could lead to better management of side effects from cancer treatments, allowing patients to continue effective therapies without debilitating interruptions.
How similar studies have gone: Preliminary studies have shown promise in using biomarkers to predict irAEs, indicating that this approach may lead to significant advancements in patient care.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Naing, Aung — University of Tx Md Anderson Can Ctr
- Study coordinator: Naing, Aung
Related research
Other NIH-funded projects on the same topics.
-
HIV-related cervical cancer screening and care in LMICs (AVANÇO HAMRC)
A multi-country effort to build sustainable research infrastructure and low-cost cervical cancer screening and treatment methods for women living with HIV in Brazil and Mozambique.
-
HIV-associated cervical cancer care infrastructure in LMICs
A program to build sustainable research infrastructure and bring low-cost cervical cancer screening, diagnosis, and treatment to women with HIV in Brazil and Mozambique.
-
HIV-associated cervical cancer screening and care network in LMICs
A multinational program aims to build affordable, practical cervical cancer screening, diagnosis, and treatment methods for women living with HIV in Brazil and Mozambique.
-
Mapping HIV-like SIV Reservoirs in the Brain with Advanced PET Imaging
This project develops brain-targeted imaging probes to map SIV reservoirs in the central nervous system of infected macaques, aiming to improve our understanding of how HIV-like viruses hide in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Germline clues to skin-related immune side effects from cancer immunotherapy
This grant looks for genetic clues in people treated with immune checkpoint inhibitors to understand why some develop skin-related immune side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.